Reaction

Lichenoid Keratosis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,228 reports · 58 co-occurring drugs

As of the last recalculation, Lichenoid Keratosis appears in 2,228 FAERS reports alongside 58 co-occurring drug terms. The strongest observed disproportionality signal is PEMBROLIZUMAB (PRR 35.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Pembrolizumab	343	35.8	35.9
Pemetrexed	77	34.7	34.8
Pemetrexed Disodium	125	32.4	32.5
Atovaquone	21	24.6	24.7
Pyrazinamide	24	24.1	24.2
Nivolumab	196	20.7	20.7
Durvalumab	43	20.1	20.2
Rifampicin	20	18.6	18.7
Carboplatin	219	17.8	17.8
Isoniazid	27	15.7	15.8
Apalutamide	18	14.4	14.4
Mometasone	27	13.9	13.9
Paclitaxel (Aibumin-Bound)	107	12.7	12.7
Desloratadine	14	12.3	12.3
Ipilimumab	55	12.2	12.2
Efavirenz	14	11.8	11.8
Atezolizumab	48	11.8	11.8
Candesartan	42	11.2	11.2
Paclitaxel	107	10.6	10.6
Sirolimus	14	9.8	9.8
Captopril	10	9.8	9.8
Melphalan	23	9.5	9.5
Melphalan Hydrochloride	25	9.4	9.4
Methylprednisolone Acetate	8	9.4	9.4
Clobetasol Propionate Ointment Usp, 0.05%	10	9.1	9.1
Clobetasol Propionate	10	9.1	9.1
Imatinib	17	9.1	9.1
Busulfan	15	9.0	9.0
Fludarabine Phosphate	34	8.2	8.2
Daptomycin	8	8.1	8.1
Rifampin	12	7.7	7.7
Candesartan Cilexetil	21	7.5	7.5
Oxazepam	17	7.4	7.4
Ramipril	94	7.4	7.4
Fondaparinux Sodium	6	6.9	6.9
Lamivudine Oral	18	6.7	6.7
Tenofovir Disoproxil Fumarate Tablets	6	6.5	6.5
Imatinib Mesylate	19	6.4	6.4
Fenofibrate	24	6.4	6.4
Valacyclovir	26	5.9	5.9
Temozolomide	13	5.8	5.8
Clobazam	15	5.8	5.8
Daratumumab	24	5.7	5.7
Lacosamide	22	5.6	5.6
Brentuximab Vedotin	6	5.5	5.5
Lamivudine	18	5.5	5.5
Levetiracetam	76	5.5	5.5
Fluorouracil Cream, 0.5%	39	4.8	4.8
Fluorouracil	39	4.8	4.8
Dorzolamide Hydrochloride And Timolol Maleate	4	4.7	4.7
Dabrafenib	9	4.0	4.0
Darbepoetin Alfa	22	3.8	3.8
Polatuzumab Vedotin	4	3.8	3.8
Obinutuzumab	6	3.4	3.4
Bosutinib	3	3.1	3.1
Vemurafenib	4	3.1	3.1
Ruxolitinib	23	3.0	3.0
Axicabtagene Ciloleucel	3	2.8	2.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.